{"id":454791,"date":"2021-03-10T09:03:14","date_gmt":"2021-03-10T14:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454791"},"modified":"2021-03-10T09:03:14","modified_gmt":"2021-03-10T14:03:14","slug":"immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/","title":{"rendered":"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\n\u00a0<b>ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company<\/b><\/p>\n<p>CULVER CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunitybio.com%2F&amp;esheet=52393658&amp;newsitemid=20210310005337&amp;lan=en-US&amp;anchor=ImmunityBio%2C+Inc&amp;index=1&amp;md5=6907c198af8e639d17d46f0b69b25ae2\">ImmunityBio, Inc<\/a>. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker.\n<\/p>\n<p>\nImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company\u2019s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term \u201cimmunological memory.\u201d\n<\/p>\n<p>\nThe company\u2019s broad-based platforms are based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells.\n<\/p>\n<p>\nImmunityBio has a broad immunotherapy clinical pipeline of over 40 clinical trials in Phase I, II and III development across 19 indications in solid and liquid cancers and infectious diseases. The clinical-stage pipeline and intellectual property portfolio spans 17 first-in-human antibody cytokine fusion proteins, chemo immuno-modulators, vaccine vectors, and cell therapies in 25 Phase II and III clinical trials. Anktiva\u2122 (ImmunityBio\u2019s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).\n<\/p>\n<p>\nImmunityBio is a leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise, ready-to-scale facilities, extensive and seasoned R&amp;D, clinical trial, and regulatory operations and development teams. For more information, please visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.immunitybio.com%2F&amp;esheet=52393658&amp;newsitemid=20210310005337&amp;lan=en-US&amp;anchor=www.immunitybio.com&amp;index=2&amp;md5=a498a59b1758b4f6daa7d83432c61225\">www.immunitybio.com<\/a><\/p>\n<p><b>Forward Looking Statements <\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccontinues\u201d, \u201ccould\u201d, \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential\u201d, \u201cpredicts\u201d, \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio\u2019s management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger , (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger, (iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and\/or ImmunityBio\u2019s operations or operating expenses. More details about these and other risks that may impact ImmunityBio\u2019s business are described under the heading \u201cRisk Factors\u201d in the Company\u2019s Form 8-K filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) on March 10, 2021 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52393658&amp;newsitemid=20210310005337&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=17b0c3dda395b1f73fd75369ebe1cf92\">www.sec.gov<\/a>. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210310005337\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210310005337\/en\/<\/a><\/span><\/p>\n<p><b>Investors<br \/>\n<br \/><\/b>Sarah Singleton<br \/>\n<br \/>ImmunityBio, Inc.<br \/>\n<br \/>844-696-5235, Option 5\n<\/p>\n<p><b>Media<br \/>\n<br \/><\/b>Amy Jobe, Ph.D.<br \/>\n<br \/>LifeSci Communications<br \/>\n<br \/>315-879-8192<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ajobe@lifescicomms.com\">ajobe@lifescicomms.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology Health Genetics Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210310005337\/en\/760385\/3\/ImmunityBio.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company CULVER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker. ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company\u2019s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term \u201cimmunological memory.\u201d The company\u2019s broad-based platforms are based on the foundation of four separate modalities: Antibody cytokine &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454791","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u00a0ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company CULVER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker. ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company\u2019s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term \u201cimmunological memory.\u201d The company\u2019s broad-based platforms are based on the foundation of four separate modalities: Antibody cytokine &hellip; Continue reading &quot;ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T14:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company\",\"datePublished\":\"2021-03-10T14:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/\",\"name\":\"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-10T14:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/","og_locale":"en_US","og_type":"article","og_title":"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company - Market Newsdesk","og_description":"\u00a0ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company CULVER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker. ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company\u2019s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term \u201cimmunological memory.\u201d The company\u2019s broad-based platforms are based on the foundation of four separate modalities: Antibody cytokine &hellip; Continue reading \"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T14:03:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company","datePublished":"2021-03-10T14:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/","name":"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-10T14:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454791"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454791\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}